Émilie Orlhac
Be part of YCare Day on November 2nd!
1 Oct 2024
Golf clubs across Québec unite on the greens...
18 Jul 2024
Health Canada Accepts for Review New Drug Submission...
Health Canada has agreed to review a New Drug Submission (NDS) for Tofersen, for the treatment of amyotrophic lateral sclerosis (ALS) in adults with a mutation in the superoxide dismutase 1 (SOD1) gene.
A regulatory decision on the New Drug Submission is expected in early 2025. If approved, this therapy will become the first treatment in Canada to target a genetic cause of ALS.
Read the...
19 Mar 2024
A Message of Hope and Unity in the...
Today, Amylyx announced that their Phase 3 PHOENIX trial, a global, 48-week, randomized, placebo-controlled study of AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine; also known as ALBRIOZA) in people living with ALS, did not meet its prespecified primary or secondary endpoints.
It's understandable if this outcome has left us all feeling disheartened and discouraged. Now, more than ever,...
8 Mar 2024
Uniting our voices to affect change together
28 Feb 2024
Registrations are now open for the RIDE and...
23 Feb 2024